IFNA1 and autoimmune disease: Genetic approaches, such as CRISPR, have demonstrated significant efficacy in correcting gene mutations or dysregulation within key modulators of cytosolic nucleic acid sensing pathways, thereby reducing aberrant IFN production and attenuating symptoms of autoimmune disorders [12].